CRAI dividend yield: 4.00%. PFE dividend yield: 6.77%. CRAI is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in CRAI shares. Pfizer offers one of the highest dividend yields among blue-chip pharma companies. Post-COVID revenue normalization has pressured earnings, but the dividend has been maintained. Pfizer's acquisition of Seagen adds oncology depth. With 14+ consecutive years of no dividend cuts, income investors see the high yield as an opportunity.
CRAI is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in CRAI shares.
Pfizer offers one of the highest dividend yields among blue-chip pharma companies. Post-COVID revenue normalization has pressured earnings, but the dividend has been maintained. Pfizer's acquisition of Seagen adds oncology depth. With 14+ consecutive years of no dividend cuts, income investors see the high yield as an opportunity.
Is CRAI or PFE better for dividend income in 2026?
CRAI currently offers a 4.00% yield (2.00/share/year) while PFE offers 6.77% (1.68/share/year). PFE provides higher current income. However, CRAI has grown its dividend faster (5% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in CRAI vs PFE earn per year?
With $10,000 invested today: CRAI pays approximately $400/year. PFE pays approximately $677/year. With DRIP reinvestment over 10 years, these grow to $899/year (CRAI) and $5,820/year (PFE).
Does CRAI or PFE pay monthly dividends?
CRAI pays quarterly dividends. PFE pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this CRAI vs PFE comparison by email
Save your analysis + get weekly dividend insights. Free forever.